CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of “Hold” from Analysts

CRISPR Therapeutics AG (NASDAQ:CRSP) has been assigned an average recommendation of “Hold” from the twenty-one ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $73.11.

A number of research analysts have recently issued reports on the stock. Citigroup reduced their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a research report on Tuesday, February 18th. TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price on the stock in a report on Wednesday, February 12th. JMP Securities reiterated a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Truist Financial boosted their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. Finally, Morgan Stanley upped their price objective on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research note on Friday, February 14th.

CRISPR Therapeutics Trading Up 1.7 %

CRSP opened at $42.82 on Thursday. The company has a fifty day simple moving average of $43.06 and a 200 day simple moving average of $45.51. The firm has a market cap of $3.67 billion, a price-to-earnings ratio of -9.80 and a beta of 1.77. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $75.91.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, analysts forecast that CRISPR Therapeutics will post -5.16 earnings per share for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 2,850 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $120,897.00. Following the completion of the transaction, the general counsel now owns 77,530 shares in the company, valued at approximately $3,288,822.60. This represents a 3.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director John Greene bought 7,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 26th. The shares were bought at an average price of $44.85 per share, with a total value of $313,950.00. Following the transaction, the director now directly owns 7,000 shares in the company, valued at $313,950. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 32,381 shares of company stock valued at $1,608,243 in the last ninety days. Company insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors have recently bought and sold shares of the business. Boston Family Office LLC boosted its position in CRISPR Therapeutics by 2.2% in the 3rd quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock valued at $459,000 after buying an additional 213 shares during the last quarter. Bedell Frazier Investment Counselling LLC raised its stake in CRISPR Therapeutics by 0.8% during the 3rd quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock worth $1,238,000 after buying an additional 218 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of CRISPR Therapeutics by 1.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock valued at $586,000 after purchasing an additional 231 shares during the period. Intellectus Partners LLC raised its stake in shares of CRISPR Therapeutics by 3.6% in the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock valued at $281,000 after purchasing an additional 250 shares during the period. Finally, Farrow Financial Inc. grew its holdings in shares of CRISPR Therapeutics by 1.4% in the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock valued at $777,000 after acquiring an additional 270 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.